FDA Advisory Committee Recommends Approval of New Alzheimer’s Drug

By | June 11th, 2024

Eli Lilly’s anti-amyloid Alzheimer's drug donanemab may be FDA-approved as soon as this summer. An advisory committee to the agency just unanimously recommended its approval.

Today, the Food and Drug Administration’s (FDA) eleven-person advisory committee unanimously voted, (11-0) that Eli Lilly’s anti-amyloid Alzheimer’s drug donanemab was effective, and that the benefits of the drug outweigh the risks for people with the earliest stages of Alzheimer’s disease.

The agency is expected to make their final decision on approving the drug in the next few weeks. 

While the drug, which will be given a brand name when it his the market, did not stop the progression of the disease, in the trial, it slowed the progression of Alzheimer’s disease by a small amount.

The study split patients based on the amount of tau tangles in their brain. They measured this protein biomarker using a tau PET scan. Patients with low to medium levels of tau showed more slowing of symptoms than those with high levels of tau. 

Tau PET scans are expensive procedures that are not covered by Medicare, but the advisory committee’s members said they did not think it would be necessary for patients to receive a tau PET scan in order to determine their eligibility for donanemab.

Despite the positive results, committee members raised concerns about the low number of non-white patients in the trial. There is still uncertainty over when clinicians should test to see whether amyloid has been cleared for the brain, and uncertainty over whether patients might need to go back onto treatment after a while. They also emphasized the need for collecting more data.

Sneak Peek of Trial Data for Alzheimer’s Drug Donanemab

Alzheimer’s patients in areas of the U.S. with the highest rates of the disease have limited access to infusion centers that offer Leqembi. Time will tell whether patients prescribed donanemab will face similar access hurdles.

If you find our articles and interviews helpful, please consider becoming a supporting member of our community. Frustrated by the lack of an editorially independent source of information on brain health and Alzheimer’s disease, we decided to create Being Patient. We are a team of dedicated journalists covering the latest research on Alzheimer’s, bringing you access to the experts and elevating the patient perspective on what it’s like to live with dementia.

Please help support our mission.

Leave a Reply

We are glad you have chosen to leave a comment. Please keep in mind that comments are moderated according to our comment policy.